NCT06924710 Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD
| NCT ID | NCT06924710 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Cancer Hospital & Institute |
| Condition | NSCLC |
| Study Type | INTERVENTIONAL |
| Enrollment | 286 participants |
| Start Date | 2025-04-06 |
| Primary Completion | 2029-06-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 286 participants in total. It began in 2025-04-06 with a primary completion date of 2029-06-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
It is a prospective, multicenter, randomized controlled trial to investigate the predictive value of MRD on adjuvant therapy. Stage IA2-II resected NSCLC patients will undergo two-round MRD tests after surgery, first in 3-7 days and second in 1 month after surgery. And patients who confirm two-round landmark undetectable MRD will be enrolled and randomly assigned to the conventional treatment group or the adaptive therapy group . Patients in the the adaptive therapy group will undergo closely MRD and imaging monitoring without adjuvant therapy if the MRD was negative.
Eligibility Criteria
Inclusion Criteria: * Stage IA2-II non-small cell cancer patients who after complete resection. * Two-round MRD tests confirm landmark undetectable MRD * Expected survival ≥24 months * ECOG PS 0-1 * Willing to accept MRD monitoring every 3 months for a total of 2 years after surgery Exclusion Criteria: * Patients who had previously undergone radiotherapy or chemotherapy or any other anti-tumor therapy * Patients with a history of other malignancies in the past 5 years * Any unstable systemic disease (eg, active infection, high-risk hypertension, unstable angina, congestive heart failure, etc.) or other conditions that investigators considered would limit the ability of the patient to participate in the study
Contact & Investigator
Shaohua Ma, M.D.
PRINCIPAL INVESTIGATOR
Peking University Cancer Hospital & Institute, Beijing 100142, China
Frequently Asked Questions
Who can join the NCT06924710 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying NSCLC. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06924710 currently recruiting?
Yes, NCT06924710 is actively recruiting participants. Contact the research team at shenluyan@pku.edu.cn for enrollment information.
Where is the NCT06924710 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06924710 clinical trial?
NCT06924710 is sponsored by Peking University Cancer Hospital & Institute. The principal investigator is Shaohua Ma, M.D. at Peking University Cancer Hospital & Institute, Beijing 100142, China. The trial plans to enroll 286 participants.